Fig. 7

The 5-year overall survival (OS) and disease-free survival (DFS) rates among stage II CRC patients according to adjuvant chemotherapy (ACT). We divided the stage II CRC patients into ACT and surgery alone (SA) groups. In stage II LVI− patients, no significant difference existed in the 5-year OS and DFS rates between the ACT and SA groups (5-year OS, 81.4% vs. 78.7%; P = 0.738 (a) and 5-year DFS, 79.1% vs. 77.9%, P = 0.896; (b)). When LVI+ patients were analyzed, the ACT group had significantly higher 5-year OS and DFS rates than the SA group (5-year OS, 66.7% vs. 40.9%, P = 0.004, (c) and 5-year DFS, 64.1% vs. 36.3%, P = 0.002; (d))